Nanjing Univ. of Chinese Medicine FLT3 compound C14

Nanjing Univ. of Chinese Medicine FLT3 compound C14: sourced facts only. name: "In light of these data, compound C14 represents a novel covalent FLT3 kinase inhibitor for targeted therapy of AML." [PMID:35863236]; target: "In light of these data, compound C14 represents a novel covalent FLT3 kinase inhibitor for targeted therapy of AML." [PMID:35863236]; developer: "National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China." [PMID:35863236]; stage: "The antitumor activities indicated that C14 had strong inhibitory activity against the human acute myeloid leukemia (AML) cell lines MOLM-13 (IC50 = 507 nM) harboring FLT3-ITD mutant, as well as MV4-11 (IC50 = 325 nM) bearing FLT3-ITD mutation." [PMID:35863236]